Literature DB >> 9828220

Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats.

M G Swain1, P Beck, K Rioux, T Le.   

Abstract

"Sickness behaviors" such as lethargy, fatigue, and malaise occur commonly in patients with cholestatic liver diseases and contribute significantly to the morbidity associated with these diseases. However, the cause of these symptoms is unknown. Interleukin-1beta (IL-1beta) released within the brain has been implicated in the genesis of a number of "sickness behaviors," including malaise and lethargy. Therefore, we investigated whether experimental cholestatic liver disease caused by bile duct resection (BDR) in rats is associated with enhanced central sensitivity to IL-1beta-induced "sickness behaviors." The central infusion of IL-1beta at a dose that produced an insignificant decrease in locomotor activity in control rats produced a striking reduction in locomotor activity in cholestatic rats. The anorectic response to central IL-1beta infusion was similar in cholestatic and noncholestatic animals and did not parallel our locomotor activity findings. Therefore, cholestatic liver injury is characterized by augmented central responsiveness to IL-1beta with respect to a decrease in locomotor activity. These findings may explain, at least in part, the high incidence of symptoms such as fatigue, malaise, and lethargy that occur in cholestatic patients and may open novel future avenues for their treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828220     DOI: 10.1002/hep.510280616

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

Review 1.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

4.  Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.

Authors:  D E J Jones; N Bhala; J Burt; J Goldblatt; M Prince; J L Newton
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

5.  Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial.

Authors:  Jayant A Talwalkar; Jessica J Donlinger; Andrea A Gossard; Jill C Keach; Roberta A Jorgensen; Janice C Petz; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

6.  Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels.

Authors:  D M Forton; N Patel; M Prince; A Oatridge; G Hamilton; J Goldblatt; J M Allsop; J V Hajnal; H C Thomas; M Bassendine; D E J Jones; S D Taylor-Robinson
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

7.  Fatigue in chronic cholestasis.

Authors:  P Milkiewicz; E J Heathcote
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 8.  Fatigue in liver disease: pathophysiology and clinical management.

Authors:  Mark G Swain
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

9.  TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis.

Authors:  Joanna Raszeja-Wyszomirska; Ewa Wunsch; Agnieszka Kempinska-Podhorodecka; Daniel S Smyk; Dimitrios P Bogdanos; Malgorzata Milkiewicz; Piotr Milkiewicz
Journal:  Clin Dev Immunol       Date:  2013-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.